WHY IS THIS COMBINATION FAILING HIV RESISTANCE

1
WHY IS THIS COMBINATION FAILING?HIV RESISTANCE

• Ernesto J. Lamadrid, MD, AAHIVS
• Faculty Florida/Caribbean AETC

2
Disclosure of Financial Relationships

• This speaker has no significant financial
  relationships with commercial entities to
  disclose.

This slide set has been peer-reviewed to ensure
that there areno conflicts of interest
represented in the presentation.
3
Antiretroviral Therapy 2008

• 27 antiretrovirals available
• Regimens easier to use and adhere to
• Lifetime therapy
• Treatment fatigue
• Poor adherence
• Development of resistance

4
Antiretroviral Resistance

• Decreased ability of antiretroviral agent to
  suppress replication of patients virus
• Can be transmitted from a patient with a
  drug-resistant strain or can develop under
  selective drug pressure
• Not an all or none phenomenon, can be relative to
  drug concentration

5
What is Treatment Failure?

• Treatment failure can be classified as
• Virologic a confirmed HIV RNA level gt400
  copies/mL after 24 weeks, gt50 copies/mL after 48
  weeks, or a repeated HIV RNA level gt400 copies/mL
  after prior suppression of viremia to lt400
  copies/mL
• Immunologic persistent decline or lack of rise
  in CD4 count above a certain threshold over a
  period of time
• Clinical viral suppression with intolerable side
  effects of ARVs compromising quality of life.
  Also defined as occurrence of HIV-related
  clinical events after 3 months on therapy

6
Types of Resistance Tests

• Genotype
• HIV gene sequencing of the patients virus to
  detect mutations known to confer drug resistance
• Phenotype
• Measures ability of a recombinant virus derived
  from the patient sample to grow in different
  concentrations of antiretroviral drugs
• Virtual phenotype
• Use of genotype results to predict phenotypic
  susceptibility based originally on database of
  paired genotype and phenotype data or, more
  recently, through scores derived from linear
  regression analysis

Hirsch MS, et al. Clin Infect Dis.
200337113-128.
7
Limitations of Resistance Testing

• Lack of uniform quality controls across different
  laboratories
• High cost compared with other tests routinely
  done in HIV care
• Cannot be reliably performed with HIV RNA lt
  500-1000 copies/mL
• May not be able to detect minority populations of
  resistant virus if they account for lt 20 of the
  sampleespecially common after drug
  discontinuation
• Resistant strains that are in viral reservoirs
  also not detected

DHHS Guidelines, May 2006. Devereux HL, et al.
AIDS 199913F123-F127.
8
Interpreting Resistance Tests A Step-by-Step
Approach

• Collect all prior resistance tests for review
• Make sure current treatment, level of adherence,
  HIV RNA, and CD4 cell count are known
• Take each drug class individually
• Start with NNRTIs
• Next is NRTIs M184V alone vs broader resistance
• Finish with PIs Is resistance present at all? If
  so, is cross-resistance minimal, moderate, or
  high?
• Choose new regimen incorporating resistance data,
  treatment history, and results from clinical
  studies

9
Resistance Testing Guidelines Treatment-Naive
Patients
10
DHHS Panel Recommendations

• Resistance testing is recommended for persons
  with HIV infection when they enter into care
  regardless of whether therapy will be initiated
  immediately (AIII). If therapy is deferred,
  repeat testing at the time of antiretroviral
  therapy initiation should be considered (CIII).
• A genotypic assay is generally preferred for
  antiretroviral-naïve persons (AIII)
• Resistance testing should be performed to assist
  in selecting active drugs when changing
  antiretroviral regimens in cases of virologic
  failure (AII).

Guidelines for the Use of Antiretroviral Agents
in HIV-1-Infected Adults and Adolescents January
29, 2008
11
DHHS Panel Recommendations (cont)

• Resistance testing should also be performed when
  managing suboptimal viral load reduction (AII)
• Drug resistance testing in the setting of
  virologic failure should be performed while the
  patient is taking his/her antiretroviral drugs,
  or immediately (i.e., within 4 weeks) after
  discontinuing therapy (AII)
• Genotypic resistance testing is recommended for
  all pregnant women prior to initiation of therapy
  (AIII) and for those entering pregnancy with
  detectable HIV RNA levels

Guidelines for the Use of Antiretroviral Agents
in HIV-1-Infected Adults and Adolescents January
29, 2008
12
Resistance Testing Recommended
Guidelines for the Use of Antiretroviral Agents
in HIV-1-Infected Adults and Adolescents January
29, 2008
13
Resistance Testing Not Recommended
DHHS Guidelines for the Use of Antiretroviral
Agents in HIV-1-Infected Adults and Adolescents.
October 10th, 2006. www.aidsinfo.nih.gov
14
Mutations Selected by nRTIs
2006 IAS
15
Mutations Selected by NNRTIs
2006 IAS
16
Mutations Selected by PIs
82
2006 IAS
FIRV
17
Mutations Selected by PIs (cont)
2006 IAS
18
Case 1

• 40-yr-old man, new HIV diagnosis, antiretroviral
  therapy naive
• Last negative test in 1999 sexually active with
  other men
• Construction worker with alternating shifts
• CD4 1100 cells/mm3 HIV RNA 5500 copies/mL
• Hepatitis C Ab () w/ normal transaminases
• What is your next step?

19
(No Transcript)
20
Resistance Issues in Naive Patients

• When should clinicians test for resistance in
  HIV-1-infected treatment-naive patients?
• How often does transmission of resistant variants
  occur?
• What is the best method for testing for resistant
  variants and how to interpret results?
• What benefit is derived from the knowledge gained
  by resistance testing in treatment-naive
  patients?

clinicalcareoptions.com/hiv
21
Resistance Issues in Naive Patients

• When should clinicians test for resistance in
  HIV-1-infected treatment-naive patients?
• How often does transmission of resistant variants
  occur?
• What is the best method for testing for resistant
  variants and how to interpret results?
• What benefit is derived from the knowledge gained
  by resistance testing in treatment-naive
  patients?

clinicalcareoptions.com/hiv
22
Resistance Testing in Rx-Naive Patients Should Be
Done at Diagnosis
2002 New Dx
2005 Still Rx Naive
23
Re-emergence vs Reversion of Wild-Type Virus
Initial wild-type
24
Considerations Regarding Testing for Transmitted
Resistance

• Practice setting
• Lower threshold in urban areas or areas that
  commonly treat HIV
• Patient characteristics
• Infection source and antiretroviral history of
  source
• Duration of infection
• MSM may be more likely to acquire resistant
  variants than women or IDUs
• Travel history
• If CD4 count lt 100 cells/mm3 and infection
  duration gt 10 years, resistance test unlikely to
  guide therapy

25
Demographic Differences

• Different prevalence in different populations
• Incidence of resistant virus in SHCS by subgroup
• Women (10.4)
• Men (2.6)
• Heterosexual contact (6.1)
• Homosexual contact (11.3)
• IDU (13)

Yerly S, et al. AIDS. 2001152287-2292.
26
Resistance Issues in Naive Patients

• When should clinicians test for resistance in
  HIV-1-infected treatment-naive patients?
• How often does transmission of resistant variants
  occur?
• What is the best method for testing for resistant
  variants and how to interpret results?
• What benefit is derived from the knowledge gained
  by resistance testing in treatment-naive
  patients?

clinicalcareoptions.com/hiv
27
Increasing Prevalence of Resistant Virus In Newly
Infected Patients Genotypic Analysis
25
22.7
1995-1998
20
1999-2000
15.9
15
Presence of major resistance mutations ()
10.2
9.1
10
8.5
8.0
7.3
3.8
5
1.7
0.9
0
Any ARV
NRTIs
NNRTIs
PIs
MDR
Little SJ, et al. N Engl J Med. 2002347385-394.
28
Resistance Issues in Naive Patients

• When should clinicians test for resistance in
  HIV-1-infected treatment-naive patients?
• How often does transmission of resistant variants
  occur?
• What is the best method for testing for resistant
  variants and how to interpret results?
• What benefit is derived from the knowledge gained
  by resistance testing in treatment-naive
  patients?

clinicalcareoptions.com/hiv
29
What Resistance Test to Use in Naïve Patients?

• The available resistance tests are genotype and
  phenotype.
• The genotype identifies the mutations present in
  the viral genome
• The phenotype grows the virus in presence of the
  different drugs
• Genotype is the test used to measure resistance
  in naïve patients

30
New dx, ART naive
31
Resistance Issues in Naive Patients

• When should clinicians test for resistance in
  HIV-1-infected treatment-naive patients?
• How often does transmission of resistant variants
  occur?
• What is the best method for testing for resistant
  variants and how to interpret results?
• What benefit is derived from the knowledge gained
  by resistance testing in treatment-naive
  patients?

clinicalcareoptions.com/hiv
32
Impact of Baseline Resistance on Treatment
Outcome FTC-301A Study
Naive pts, baseline VL gt 5000 copies/mL
Incidence of Virologic Failure ()
Any
NNRTI
NRTI
K103N
Any
NNRTI
NRTI
K103N
Mutation type
FTC ddI EFV n 270
d4T ddI EFV n 276
Borroto-Esoda K, et al. CROI 2004. Abstract 672.
33
Summary Points

• Up to one quarter of acutely or recently infected
  patients have detectable drug resistance
  mutations
• Among chronically infected patients, detectable
  drug resistance mutations are generally present
  in 5 to 10
• May reflect acquisition of HIV when transmission
  of resistant strains was less common, and/or
  back-mutation of transmitted resistant virus to
  WT
• These rates support the use of resistance testing
  in treatment-naive individuals, particularly in
  recently infected patients
• Prevalence of transmitted resistance varies by
  population, and may have declined in recent years

34
New dx, ART naive
35
NNRTIs Important Mutations

• Most common K103N, Y181C
• These also lead to NNRTI resistance L100I,
  V106A, V108I, Y188L, G190A/S, P225H
• Other substitutions in loci close to the above
  may induce NNRTI resistance

36
Clinical Consequences of Resistance to
First-Generation NNRTIs

• Important points about NNRTI resistance
• Extensive cross-resistance between drugs
• No impairment of replication capacity or ongoing
  antiviral effect once resistance develops
• Why resistance reports may be misleading
• NVP failures often select for Y181C EFV still
  active phenotypically
• G190A may lead to DLV hypersusceptibility rarely
  present in isolation

37
Clinical Consequences of Resistance to
First-Generation NNRTIs (contd)

• But most studies suggest any prior NNRTI
  resistance reduces subsequent response to current
  NNRTIslow levels of K103N may not be detected by
  current assays
• Therefore, sequencing not a practical option with
  first-generation NNRTIs (EFV, NVP, DLV)
• NNRTIs in a failing regimen should be stopped to
  prevent selection of mutations that may impair
  response to second- generation agents

Palmer S, et al. J Clin Microbiol.
200543406-413. Vingerhoets J, et al. CROI 2006.
Abstract 154.
38
Case 2

• 29-yr-old female, hotel employee, with ITP
• Pretreatment lab values CD4 210 HIV RNA
  88,000 PLT 27K
• Antiviral history
• 2000 treated with ZDV/3TC NVP, adherent during
  pregnancy with HIV RNA lt 400 PLT gt 100K
• Started taking ART intermittently after her baby
  was born HIV negative
• Returned for follow-up when she noted new rash
• PE scattered petechiae, otherwise normal
  platelet count 14K CD4 350 HIV RNA 45,000
• Whats the next step?

39
Current Rx ZDV/3TC, NVP HIV RNA 45,000, CD4 350
40
The Special Case of M184V

• M184V emerges rapidly in nonsuppressive regimens
  containing 3TC or FTC
• Associated with high-level phenotypic resistance
  to 3TC/FTC in vitro but also reduction in
  replication capacity, HIV RNA lt baseline
• Increases susceptibility to ZDV, d4T, TDF
  decreases (slightly) ABC, ddI, but all NRTIs have
  some activity

41
M184V Increases Susceptibility to d4T, ZDV, and
TDF
42
Which NRTI Combinations Should Be Used After
M184V?

• No prospective data on the optimal NRTI choice
• Based on results of 3TC discontinuation studies
  and resistance testing, the following are likely
  to be most active
  -TDF/ABC
• -TDF/FTC/ZDV
• -TDF/ZDV
• If above cannot be used, these combinations would
  also retain activity
• DDI/TDF
• ZDV/3TC/ABC
• TDF/ddI should be avoided even though both retain
  activity vs M184V-containing viruses

43
Case 2

• 29-yr-old female, hotel employee, with ITP
• Pretreatment lab values CD4 210 HIV RNA
  88,000 PLT 27K
• Antiviral history
• 2000 treated with ZDV/3TC NVP, adherent during
  pregnancy with HIV RNA lt 400 PLT gt 100K
• Started taking ART intermittently after her baby
  was born HIV negative
• Returned for follow-up when she noted new rash
• PE scattered petechiae, otherwise normal
  platelet count 14K CD4 350 HIV RNA 45,000
• Whats the next step?

44
What Combination will you Choose?

• Tenofovir emtricitabine efavirenz
• Tenofovir emtricitabine atazanavir/ritonavir
• Zidovudine abacavir fosamprenavir/ritonavir
• Tenofovir emtricitabine abacavir
• atazanavir/ritonavir
• e) Tenofovir didanosine lopinavir/ritonavir
  

45
(No Transcript)
46
Thank you!!!
?